Biotech Stocks Touching New Highs: BioSpecifics Technologies (NASDAQ:BSTC), NanoString Technologies (NASDAQ:NSTG), Celladon (NASDAQ:CLDN), Receptos (NASDAQ:RCPT)



BioSpecifics Technologies Corp. (NASDAQ:BSTC) released its earnings data on Thursday. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.17 by $0.08, Stock Ratings Network.com reports. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 1.56% in last session and finished the day at $26.72. Traded volume was 32,149.00 shares in the last session and the average volume of the stock remained 27,462.00 shares. The beta of the stock remained 0.90. BioSpecifics Technologies Corp. (NASDAQ:BSTC) insider ownership is 1.40%.

NanoString Technologies (NASDAQ:NSTG) had its target price boosted by Robert W. Baird from $23.00 to $26.00 in a report issued on Wednesday, AR Network reports. NanoString Technologies Inc. (NASDAQ:NSTG) dropped -2.77% to $21.38 yesterday on volume of 115,011.00 shares. The intra-day range of the stock was $20.82 – $22.44. NanoString Technologies Inc. (NASDAQ:NSTG) has a market capitalization of 312.49 million.

Celladon Corp (NASDAQ:CLDN) on Mar. 4 announced it has completed enrollment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN)’s stock on March 13, 2014 reported a higher of 8.27% to the closing price of $14.66. Its fifty two weeks range is $7.45 – $15.48. The total market capitalization recorded 250.82 million. The overall volume in the last trading session was 225,698.00 shares. In its share capital, Celladon Corp (NASDAQ:CLDN) has 17.11 million outstanding shares.

Receptos Inc. (NASDAQ:RCPT) on Mar. 5 provided development program updates and announced financial results for the fourth quarter and year ended December 31, 2013. On Thursday, shares of Receptos Inc. (NASDAQ:RCPT) dropped -4.99% to close the day at $50.45. Company return on investment (ROI) is 44.50% and its monthly performance is recorded as 15.55%. Receptos Inc. (NASDAQ:RCPT) quarterly revenue growth is 85.07%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone